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Abstract
p53 protects us from cancer by transcriptionally regulating tumor suppressive programs designed to either prevent the
development or clonal expansion of malignant cells. How p53 selects target genes in the genome in a context- and
tissue-specific manner remains largely obscure. There is growing evidence that the ability of p53 to bind DNA in a
cooperative manner prominently influences target gene selection with activation of the apoptosis program being
completely dependent on DNA binding cooperativity. Here, we used ChIP-seq to comprehensively profile the cistrome
of p53 mutants with reduced or increased cooperativity. The analysis highlighted a particular relevance of cooperativity
for extending the p53 cistrome to non-canonical binding sequences characterized by deletions, spacer insertions and
base mismatches. Furthermore, it revealed a striking functional separation of the cistrome on the basis of cooperativity;
with low cooperativity genes being significantly enriched for cell cycle and high cooperativity genes for apoptotic
functions. Importantly, expression of high but not low cooperativity genes was correlated with superior survival in
breast cancer patients. Interestingly, in contrast to most p53-activated genes, p53-repressed genes did not commonly
contain p53 binding elements. Nevertheless, both the degree of gene activation and repression were cooperativity-
dependent, suggesting that p53-mediated gene repression is largely indirect and mediated by cooperativity-
dependently transactivated gene products such as CDKN1A, E2F7 and non-coding RNAs. Since both activation of
apoptosis genes with non-canonical response elements and repression of pro-survival genes are crucial for p53’s
apoptotic activity, the cistrome analysis comprehensively explains why p53-induced apoptosis, but not cell cycle arrest,
strongly depends on the intermolecular cooperation of p53 molecules as a possible safeguard mechanism protecting
from accidental cell killing.
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Introduction
The prominence of the p53 gene in tumor suppression is
emphasized by its unsurpassed mutation rate in cancer cells [1]. As
a master regulatory transcription factor for anti-proliferative
programs, p53 can decide cell fate in response to a broad range
of stress stimuli, including DNA damage and oncogene activation
[1,2,3,4]. p53 prevents the accumulation of precancerous cells by
activating genes involved in cell cycle arrest (e.g. p21/CDKN1A,
GADD45A, SFN, E2F7) and apoptosis (e.g. BAX, PMAIP1/NOXA,
PUMA) or repressing cell proliferation genes [5]. While gene
activation is well-studied, the mechanism of p53-dependent target
gene repression is still poorly understood and both direct and
indirect models are discussed [5,6]. On the one hand, p53 prevents
genes from becoming activated by directly binding to promoters or
distal enhancer elements - thereby competing with other activating
transcription factors and components of the basic transcriptional
machinery - or by recruiting histone-modifying enzymes with
repressive functions such as mSin3A [5]. On the other hand, p53
indirectly represses proliferation genes by upregulation of several
coding (p21/CDKN1A, E2F7) and non-coding RNAs (miR-34
family, lincRNA-p21) [7,8,9,10,11,12].
Sequence specific DNA binding of p53 requires a DNA motif
that consists of two decameric half-sites (RRRCWWGYYY;
R=A/G, W=A/T, Y=C/T) separated by an optional spacer
of additional base pairs to form a full-site [13]. Previous in vitro
studies demonstrated that the central CWWG defines the
torsional flexibility of the DNA and thus influences p53’s
binding affinity [14]. While a CATG sequence is flexible and
therefore bound with high affinity, the other possible CWWG
sequences are not [15]. In fact, it has been suggested that the
inflexible CWWG sequences and spacer containing sites require
a higher binding energy and therefore represent low affinity p53
binding sites [14,15,16,17]. Interestingly, high affinity p53
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motifs are specifically enriched among pro-arrest genes, whereas
the promoters of pro-death targets predominantly contain low
affinity sites [13,16,18]. Despite these biophysical differences
between p53 binding sequences, it remains unclear at present
how p53 molecularly distinguishes between distinct target genes
to bind and activate a selected set.
Structurally, p53 proteins assemble into an asymmetric
tetramer that can be described as a dimer of symmetric dimers.
Tetramerization is mediated via the C-terminal oligomerization
domains and further stabilized through interactions between
neighboring DNA binding domains [19,20]. In detail, oppositely
charged amino acids (Glu180, Arg181) in the H1 helices of the
DNA binding domains form an inter-molecular double salt
bridge that enables adjacent p53 molecules to interact and
cooperate when binding to DNA – a property known as DNA
binding cooperativity (Fig. 1A) [21,22,23,24]. Of note, co-
operativity has been shown to be required for p53-induced
apoptosis but not cell cycle arrest [24,25]. Furthermore, somatic
p53 mutations resulting in reduced cooperativity are found in
cancer patients, germline cooperativity mutations segregate with
cancer susceptibility in Li-Fraumeni syndrome families, and
cooperativity mutant mice are highly cancer prone, indicating
that DNA binding cooperativity is essential for proper tumor
suppression [24,25].
The aim of this study was to comprehensively characterize the
impact of DNA binding cooperativity on all p53 binding sites in
the genome (the p53 cistrome) by combined analysis of global
DNA binding (ChIP-seq) and expression data. We demonstrate
that high DNA binding cooperativity is crucial for the binding and
transactivation of low affinity binding sites in pro-apoptotic genes
with non-canonical and spacer-containing p53 motifs and also for
p53-mediated repression of mitotic and pro-survival genes. Since
both transactivation of genes with non-canonical response
elements and p53-mediated gene repression are essential for
p53-induced apoptosis, these data comprehensively explain why
p53 molecules need to cooperate for cell killing as the basis for
efficient tumor suppression.
Results
DNA binding cooperativity extends the p53 cistrome to
low affinity binding sites
To explore the role of DNA binding cooperativity for the
genome-wide binding pattern of p53, we comprehensively mapped
the binding sites of p53 proteins in different cooperativity states by
deep sequencing of immunoprecipitated chromatin (ChIP-seq).
The p53 cooperativity mutation ‘‘EE’’ (p53R181E) causes four
negatively charged glutamic acid residues to cluster at the H1 helix
interaction interface which strongly destabilizes the intermolecular
interactions and reduces DNA binding cooperativity [24].
Likewise, the mutation ‘‘RR’’ (p53E180R) brings four positively
charged arginine residues together resulting in a similar destabi-
lization and low degree of cooperativity. Importantly, combined
expression of EE and RR (EE/RR) results in mixed tetramers in
which one negatively and one positively charged H1 helix interact,
resulting in a DNA binding cooperativity that slightly exceeds that
of the wild-type (wt) (Fig. 1A). Combined expression of EE and RR
therefore rescues the cooperativity defect of the EE and RR
homotetramers. Following transfection in p53-negative Saos-2
cells all p53 variants were expressed at equal levels comparable to
endogenous p53 in U2OS cells treated with the MDM2 inhibitor
nutlin-3a (Fig. 1B) [26]. ChIP sequencing resulted for each sample
in more than 30 M reads that were mapped to the genome. p53
binding peaks were called applying a stringent false discovery rate
(FDR) of 1025. Moreover, only peaks with a minimum number of
50 reads and 2-fold change versus GFP and input were considered
as binding sites. These criteria ensured the identification of only
reliably p53 bound regions. In detail, 88 peaks were determined as
EE binding sites and additional 1579 sites were bound by RR,
which together represent 1667 low cooperativity peaks (Fig. 1C).
3145 additional sites occupied by wild-type p53 together with 375
sites bound by EE/RR only, formed the 3520 high cooperativity
peaks. Thus, the number of p53 binding sites rises with increasing
DNA binding cooperativity as illustrated in the peak density plot
(Fig. 1D). When binding sites were ranked according to decreasing
EE/RR binding strength as a measure of binding affinity, EE and
RR sites clustered at the top (see heatmap in Fig. 1D), indicating
that only the high affinity p53 binding sites that were strongly
bound by EE/RR or wild-type p53 were also bound by low
cooperativity p53. Accordingly, the binding strength of wild-type
p53 to high affinity (low cooperativity) sites was significantly
stronger than to low affinity (high cooperativity) sites that were
only occupied by wild-type p53 and/or EE/RR (Fig. 1E). These
correlations between cooperativity and binding strength were also
evident on the single gene level (Fig. 1F) and confirmed in
independent validation experiments (Fig. 1G). In summary, the
genome-wide ChIP analysis revealed that DNA binding coopera-
tivity extends the number of p53 sites by enabling recruitment to
low affinity sites.
Cooperativity reduces the sequence specificity of p53
DNA binding
To explore the location of p53 binding sites in the genome, we
divided the genome into the regions: gene body, promoter, distal
and intergenic (Fig. 2A). p53 binding sites of both, low and high
affinity regions were preferentially located directly at the promoter
or within the gene body (above 70% in each group) and only
rarely at further distance indicating that low and high coopera-
tivity sites are distributed similarly across the genome (Fig. 2B).
As a previous ChIP-on-Chip analysis restricted to promoter
regions of the genome suggested that the DNA binding
cooperativity of p53 influences the sequence preference of p53
Author Summary
The tumor suppressor gene p53 counteracts tumor growth
by activating genes that prevent cell proliferation or
induce cell death. How p53 selects genes in the genome to
direct cell fate specifically into one or the other direction
remains unclear. We show that the ability of p53 molecules
to interact and thereby cooperate, influences which genes
in the genome p53 is regulating. In the absence of
cooperation, p53 only binds and regulates a limited
‘default’ set of genes that is proficient to stop cell
proliferation but insufficient to induce cell death. Cooper-
ation increases p53’s DNA binding and enables context-
dependent activation of apoptosis genes and repression of
pro-survival genes which together triggers cell death. As
the concerted effort of p53 molecules is needed, the
threshold for cell killing is raised possibly to protect us
from accidental cell loss. Thus, by shaping the genomic
binding pattern, p53 cooperation fine-tunes the gene
activity pattern to steer cell fate into the most appropriate,
context-dependent direction. The genome-wide binding
patterns of cooperating and non-cooperating p53 proteins
generated in this study provide a comprehensive list of
p53 binding sites as a resource for the scientific commu-
nity to further explore mechanisms of tumor suppression
by p53.
DNA Binding Cooperativity Modulates p53 Cistrome
PLOS Genetics | www.plosgenetics.org 2 August 2013 | Volume 9 | Issue 8 | e1003726
Figure 1. DNA binding cooperativity extends the p53 cistrome to low affinity binding sites. (A) Left: dimer of p53 DNA binding domains
(green and yellow) on the DNA (gray) (Protein Data Bank ID code 2ADY) [20]. Highlighted in blue are the H1 helices. Right: Design of complementing
p53 cooperativity mutants at glutamate E180 or arginine R181. (B) p53 Western Blot of U2OS cells treated for the indicated time with 10 mM nutlin-3a
and Saos-2 cells infected for 18 hours with the indicated p53-expressing adenoviruses. b-actin is shown as a loading control. (C) Classification of p53
binding sites identified by ChIP-seq according to cooperativity. (D) Density blot of all p53 ChIP-seq peaks arranged in order of decreasing EE/RR
binding strength. The heat map (right) depicts the classification illustrated in (C). (E) Strength of wild-type p53 binding to low and high cooperativity
regions. Depicted is a box-and-whiskers blot with 10/90 percentiles and the median; outliers are plotted as dots. n.s.; not significant. *; p-value,0.001
(ANOVA-Tukeys honest significant differences based on log-transformed normalized read counts). (F) Genome browser views of p53 binding to
DNA Binding Cooperativity Modulates p53 Cistrome
PLOS Genetics | www.plosgenetics.org 3 August 2013 | Volume 9 | Issue 8 | e1003726
[24], we further characterized the p53 sequence motif in high and
low cooperativity p53 binding sites of our genome-wide ChIP-seq
dataset. A de novo motif search within all groups of p53 peaks -
independent of the level of cooperativity - revealed a p53 motif
with significant similarity to the consensus p53 motif (JASPAR
database) (Fig. 2C). p53 motifs identified in the group of low
cooperativity sites showed high uniformity (E-value 56102177)
while motifs in high cooperativity sites were more divers (E-value
2.4610276) with the most variability in the subgroup of EE/RR-
only bound peaks (E-value 3.5610237). In fact, the EE/RR-only
motif was more similar to a p53 half-site than to a full-site.
Furthermore, a search for p53 motifs on the basis of the wild-type
p53 consensus from the present ChIP-seq analysis (Fig. 2D)
revealed a strong preference for an A in the core CWWG
sequences of each half-site that became less obvious with
increasing cooperativity (Fig. 2E). To directly compare the quality
of p53 motifs in the different cooperativity groups, we scored every
single motif instance on the basis of similarity to the wild-type p53
consensus motif using two independent algorithms (Fig. 2F).
Approximately 50% of the low cooperativity p53 binding sites
matched perfectly to the consensus in contrast to less than 20% of
the high cooperativity sites (Fig. 2F, right). In parallel, the mean
motif score as determined by the p53MH algorithm [27]
decreased with increasing cooperativity (Fig. 2C, bottom).
Moreover, whereas spacer sequences were absent in about half
of the motif instances in the low cooperativity peaks, 70 to 80% of
the motifs identified in high cooperativity peaks contained spacers
of variable length (Fig. 2C, bottom).
Together, the cistrome analysis suggests that p53 with low DNA
binding cooperativity only binds to full-site p53 DNA motifs with
high similarity to the consensus binding sequence. In contrast,
motifs occupied by highly cooperative p53 only, show reduced
similarity to the p53 consensus motif and comprise not only full
but also half-sites separated by spacers of variable length. Thus,
p53 requires high DNA binding cooperativity for binding to non-
canonical p53 motifs.
The requirement for DNA binding cooperativity
separates the p53 cistrome according to function
The genes closest to the p53 binding sites were functionally
annotated using a combination of different algorithms. Expectedly,
Ingenuity Pathway Analysis identified ‘‘p53’’ and ‘‘p53 signaling’’
as the most significant transcriptional regulator and canonical
pathway, respectively, in both cooperativity groups (Fig. 3) which
validates the two gene lists as significantly enriched for bona fide p53
target genes. Interestingly, the top biological function for low
cooperativity target genes was cell cycle progression, in contrast to
apoptosis for high cooperativity genes. The cooperativity-depen-
dent difference in biological function was further confirmed by
overlap analysis with gene sets in the Molecular Signature
Database (MSigDB, Fig. 3) and functional annotation with Gene
Ontology terms (Fig. 3). Both p53 binding site groups showed the
strongest overlap with an experimentally defined set of p53-
induced genes [28]. Importantly, genes with high affinity p53 sites
were again annotated with cell proliferation, stress and immune
responses and included well-characterized cell cycle arrest genes
such as CDKN1A and BTG2 [29,30]. In contrast, genes with low
affinity p53 peaks were associated with cell death, and apoptosis in
particular, including critical pro-apoptotic genes. Cooperativity-
dependent regulation of pro-apoptotic genes was validated for
BAX and PUMA/BBC3, two well-established apoptotic target
genes of p53 (Fig. 3B, C) [5]. Thus, the requirement for DNA
binding cooperativity, which determines the affinity towards
different p53 motifs, functionally separates the p53 cistrome into
cell cycle regulation and apoptosis.
The cistrome of wild-type p53 has been previously character-
ized in a number of different cell types under various p53-
activating conditions [31,32,33]. To explore the impact of p53
DNA binding cooperativity in a broader context, we compared
our data obtained from Saos-2 osteosarcoma cells to p53 ChIP-seq
data obtained in the breast cancer cell line MCF7 treated with 5-
fluorouracil (5FU) or MDM2 inhibitors (nutlin-3a, RITA) [32]
and the osteosarcoma cell line U2OS treated with actinomycin D
or etoposide [31] (Fig. 4). In both MCF7 and U2OS cells the p53
cistrome was strongly influenced by the type of p53-activating
stimulus and only subsets of all binding peaks were bound in a
treatment-independent manner: 3550 MCF7 common and 1611
U2OS common peaks,. Furthermore, the comparison of MCF7 and
U2OS cells revealed a pronounced cell type-specificity of the p53
cistrome so that only 1003 common peaks were bound by p53 in
both cells types. 719 (71.7%) of these common peaks were also
present in Saos-2 cells, strongly supporting the hypothesis,
previously raised by Nikulenkov et al. [32], that there is a ‘default
set’ of p53 binding sites in the genome that is bound largely
independent of treatment and cell type.
Many of the other p53 peaks that we identified in Saos-2 cells
were also present in MCF7 or U2OS cells, but often only in one
cell-type or following a specific treatment, as indicated in Fig. 4 by
the percentage of overlap. When analyzing the relative proportion
of low and high cooperativity peaks within the overlap, we found
that the common ‘default set’ of binding peaks was mostly
comprised of low cooperativity peaks, while the overlap with cell
type- or treatment-specific peak sets showed a higher percentage of
high cooperativity peaks. These data suggest that the ‘default
program’ of p53 activation, that possibly functions as a first-line
defense to genomic damage, does not require DNA binding
cooperativity, while a fine-tuned p53 response, that integrates
context-specific cues in a cell type- and stress-dependent manner,
strongly relies on DNA binding cooperativity.
Gene regulation by p53 is cooperativity-dependent
To investigate the role of DNA binding cooperativity for gene
regulation, the p53 cooperativity mutants were analyzed by
microarray-based expression profiling in combination with ChIP-
seq. 351 genes that were bound by at least one of the p53 versions
were found to be differentially regulated by more than 2-fold
(Fig. 5A, Supplemental Table S1). As shown above for the
complete p53 cistrome (Fig. 1E), DNA binding cooperativity
determined the binding strength also in the regulated part of the
cistrome, i.e. the subset of p53-bound and -regulated genes
(Fig. 5A,C). Interestingly, the vast majority of these genes (97%)
was p53-induced and not repressed. Although the EE mutant was
identified on a small number of genes by ChIP-seq, EE was no
potent mediator of gene regulation. For all other p53 proteins the
transactivation of individual genes directly correlated with binding
strength and the average degree of regulation rose with increasing
cooperativity (Fig. 5A,B). Gene regulation by the low cooperativity
mutant RR was therefore confined to the subset of genes with high
selected low (top) and high (bottom) cooperativity regions. The numbers on the y-axis of each track represent the total number of overlapping reads.
(G) Validation of ChIP-seq data by qPCR. Shown is the mean (6SD) log2-fold enrichment relative to the GFP control sample of two independent
experiments with three qPCR replicates each.
doi:10.1371/journal.pgen.1003726.g001
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Figure 2 Cooperativity reduces the sequence specificity of p53 DNA binding. (A) Classification of genomic regions. (B) Distribution of p53
binding sites across the genome on the basis of the classification depicted in (A). (C) Motif analysis within low (first column), high (second column)
and highest cooperativity p53 binding sites. The third column represents the subgroup of high cooperativity binding sites bound by EE/RR only. Top:
De novo motif search by MEME-ChIP. Depicted is the top motif (lowest E-value). Bottom: Distribution of spacer lengths and mean motif score
determined by the p53MH algorithm. (D) The p53 consensus motif generated from the top50 wild-type p53 binding sites in this study. (E) Low
cooperativity mutants display a preference for CAWG at the CWWG core of the p53 consensus binding sequence. Motifs fitting to the p53 consensus
sequence (D) within the three different cooperativity groups of binding sites defined in (C) were identified using FIMO and illustrated by WebLogo.
The pie charts represent the base distribution at positions 5 and 15 of the consensus sequence (shaded in gray). (F) Low cooperativity sites confine
better to the p53 consensus binding sequence than high cooperativity sites. Left: p53 binding sites in the indicated cooperativity groups were ranked
according to similarity (p-value) to the p53 consensus binding sequence as determined with the FIMO algorithm. Right: Percentage of peaks
containing perfect or non-canonical p53 motifs in low and high cooperativity regions, respectively, based on MAST analysis.
doi:10.1371/journal.pgen.1003726.g002
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affinity binding sites whereas high cooperativity p53 showed
additional regulation of low affinity targets (Fig. 5A). The
correlation of DNA binding cooperativity with gene regulation
was confirmed in validation experiments by RTqPCR for
several genes (Fig. 5D), some of which were previously validated
to be bound in a cooperativity-dependent manner (Fig. 1G).
Interestingly, RAD54L2, which recruits all p53 cooperativity
mutants to a similar extent, showed nevertheless cooperativity-
dependent induction suggesting that the role of cooperativity
extends beyond regulation of DNA binding and might affect
transactivation by additional mechanisms. Furthermore, al-
though TP53I3 (PIG3) displays cooperativity-dependent recruit-
ment to its binding site, it is a rare example of a target gene that
was transactivated independently of cooperativity, indicating
that low-level binding of p53 maximally activates some genes
already. It is tempting to speculate that this exception is due to
the peculiar binding of p53 to a polymorphic pentanucleotide
microsatellite in the TP53I3 promoter [34]. We conclude from
these data that cooperativity not only increases the binding site
spectrum of p53 but also gene regulation with respect to gene
number and activation level.
We next explored potential sequence, positional and functional
differences between low and high cooperativity binding sites in the
regulated subset of the cistrome (Fig. 5E). De novo motif search
discovered in both cooperativity groups a motif significantly
resembling the p53 consensus binding motif. However, the motif
was less perfect for the high cooperativity peaks and resembled
more a half-site than a full-site. In line with this, more than 50% of
the motifs in the low cooperativity group were spacer-free in
contrast to only 26% in the high cooperativity group. Different
from the genome-wide analysis, the genomic location of low and
high cooperativity binding sites across the p53-regulated genes
varied substantially. 79% of the low cooperativity sites were
located within the promoter and only 14% within the gene body,
in comparison to 56% and 30% of the high cooperativity sites,
respectively. Importantly, functional annotation again revealed a
separation of the bound and regulated genes into distinct gene
ontology categories with low cooperativity target genes being
Figure 3. The requirement for DNA binding cooperativity functionally separates the p53 cistrome. (A) Functional annotation of the
neighboring genes closest to the p53 binding sites by Ingenuity Pathway Analysis or MSigDB (the percentage denotes the proportion of genes that
overlap). The overlap with the MSigDB gene set PEREZ_TP53_TARGETS was annotated with Gene Ontology (GO). Shown are the GO terms unique for
either list. (B) Quantification of p53 binding to the BAX and PUMA/BBC3 genes by ChIP-qPCR. Shown is the mean (6SD, n = 3) binding expressed in %
of input chromatin. (C) RTqPCR quantification of BAX and PUMA/BBC3 mRNA following expression of the indicated p53 variants. Shown is the mean
(6SD, n= 3) mRNA expression normalized to GAPDH and the mock sample.
doi:10.1371/journal.pgen.1003726.g003
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annotated with cell cycle regulation and high cooperativity genes
with cell death.
Together, the DNA binding cooperativity of p53 not only
determines the number of genomic binding sites but also the
number of regulated genes, the vast majority of which are p53-
induced instead of repressed. Moreover, not only DNA binding
strength but also the level of transactivation correlates directly with
the degree of cooperativity indicating that cooperativity enhances
p53’s impact on the cistrome and transcriptome. Most important-
ly, p53-regulated genes with low and high cooperativity binding
sites differ significantly in their biological function. Transcriptional
activation of the apoptosis program requires a higher degree of
intermolecular cooperation likely as a safeguard against accidental
elimination of cells.
Clinical relevance of cooperativity for the survival of
breast cancer patients
It was previously shown by gene expression profiling that p53
mutant and wild-type breast cancer samples are molecularly
distinct and that p53-dependent transcriptional signatures not only
predict p53 status but also disease-specific survival [35]. The
correlation of superior survival with upregulated expression of
p53-induced genes was validated in multiple datasets from
independent patient cohorts [36]. Considering the role of DNA
binding cooperativity for the regulation of functionally distinct
classes of p53 target genes, we explored whether expression of low
and high cooperativity genes affects patient survival to a similar
extent. Using published microarray-based expression data from
breast cancer patients [35,37] we employed a previously described
gene set enrichment analysis (GSEA) approach to assess whether
the gene expression profile of a patient is enriched in low and/or
high cooperativity p53 target genes [38]. Kaplan-Meier curves
showed that upregulated expression of high cooperativity target
genes was significantly associated with superior survival (Fig. 6A).
Surprisingly, no such correlation was observed for low coopera-
tivity genes (Fig. 6B). These data suggest that not all p53 target
genes are equally potent in tumor suppression and that only high
cooperativity genes are able to prolong the survival of breast
cancer patients.
p53-dependent gene repression requires high DNA
binding cooperativity
In contrast to half of the p53-induced genes (476/995), less than
10% of the repressed genes (13/221) contained a p53 binding peak
in the vicinity (Fig. 7A, Supplemental Table S2). In two repressed
genes a p53 binding peak mapped to a distal enhancer element as
defined by H3K4 mono- and dimethylation, H3K27 acetylation
and DNase I hypersensitiviy (Fig. 7B) suggesting that p53 can
mediate repression through interfering with distal enhancer
activity as previously shown for mouse embryonic stem cells
[39,40,41]. However, most of the downregulated genes did not
contain a p53 binding site. Surprisingly, the level of downregu-
Figure 4. ChIP-seq meta-analysis identifies a role for cooperativity in the context-dependent fine-tuning of the p53 response. Venn
diagrams illustrate the overlap of p53 binding peaks revealed in MCF7 and U2OS cells treated with the indicated p53-activating compounds (5-
fluorouracil, 5FU; nutlin-3a; RITA; etoposide, ETO; actinomycin D, ACTD) [31,32]. The number of binding peaks and the percentage of overlap with the
total number of 5187 p53 binding sites identified in Saos-2 cells in our study are indicated. The total size of the pie charts reflects the degree of
overlap with the p53 cistrome of Saos-2 cells, while blue and red sections illustrate the proportion of high and low cooperativity binding sites,
respectively. For example, 50.3% of the 2131 p53 binding peaks identified in actinomycin D treated U2OS cells were also present in Saos-2 cells. 520
of these peaks were unique to actinomycin D treatment and 24.8% of them were present in Saos-2 cells. The majority (59.4%) of these were high
cooperativity peaks. The treatment-independent sets of p53 binding peaks were denoted MCF7 common and U2OS common, respectively. The
common peak set comprises the 1003 treatment-independent peaks that were identified in both MCF7 and U2OS cells.
doi:10.1371/journal.pgen.1003726.g004
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lation nevertheless correlated with DNA binding cooperativity
(Fig. 7C). While only three genes (KLF6, MYC, UTP15) were
identified to be repressed by the low cooperativity mutant RR,
wild-type p53 and EE/RR robustly repressed (mean 2-fold
downregulation) multiple genes associated with mitotic progression
(e.g. AURKA, AURKB, CDC20, CCNB1/2), survival (BIRC5) and
developmental regulation (TGFb and WNT signaling) (Fig. 7D,
Supp. Table S2). We conclude that p53-mediated gene repression
displays an even higher dependence on cooperativity than gene
activation.
The lack of p53 binding peaks in the vicinity of most repressed
genes suggested that p53-dependent repression is largely indirect.
As the level of downregulation was shown to be dependent on the
level of cooperativity, we predicted that downregulation is
mediated by p53 target genes which are induced in a
cooperativity-dependent manner. Several possible candidates that
have previously been implicated in p53-mediated repression such
as lincRNA-p21, miR-34a, CDKN1A and E2F7 were all induced
by p53 [7,8,9,10,12], but only E2F7 showed a cooperativity-
dependent expression pattern on the mRNA level (Fig. 7E).
Although CDKN1A was transactivated in a cooperativity-indepen-
dent manner, its gene product p21 showed a clear cooperativity-
dependent induction on the protein level (Fig. 7E,F). To
interrogate the role of these proteins for p53-mediated gene
repression, we examined the effect of CDKN1A or E2F7 depletion
(Fig. 7F). The knock-down of CDKN1A did not prevent repression
of MYC, E2F8 or GJB2, but had a slight de-repressive effect on
AURKA and BIRC5 and resulted in complete de-repression of
CDC20 (Fig. 7G). Upon depletion of E2F7 some genes were
unaffected (MYC, AURKA, BIRC5, CDC20) whereas repression of
E2F8 and GJB2 was strongly reduced (Fig. 7G). Additional
bioinformatic analysis with Ingenuity Pathway Analysis and
GeneXplain [42] in terms of p53-downregulated genes revealed
a significant enrichment of transcription factor binding sites (Sp1,
SMAD3, NF-Y) and common upstream regulators (YY1,
FOXM1) as well as additional miRNAs (miR-34, miR-145,
miR-200) several of which have been previously implicated in
transcriptional repression by p53 [43].
Since p53 engagement of a repressive effector network
comprising cell cycle inhibitors, transcriptional repressors, miR-
NAs and long non-coding RNAs is largely cooperativity-depen-
dent, DNA binding cooperativity is therefore - despite the striking
underrepresentation of p53-repressed genes in the p53 cistrome -
nevertheless a major determinant of both gene activation and
repression.
Discussion
Cooperative DNA binding by p53 is known to be essential for
p53-mediated cell death and cooperativity mutations in cancer
patients suggest a role for tumor suppression [24,44]. This is
further supported by a selective apoptosis defect and cancer
susceptibility of cooperativity mutant mice [25]. Here we used p53
H1 helix mutants in genome-wide DNA binding and expression
analyses to comprehensively profile the role of DNA binding
cooperativity for p53’s function. In line with previous data showing
that DNA binding of p53R181E (EE) is hardly detectable [22,24],
we identified only a very small number of 88 EE binding sites in
the genome compared to 4812 binding sites for wild-type p53
(Fig. 1C). Although the cooperativity-reducing p53E180R (RR)
mutation resulted in a similar DNA binding defect as the EE
Figure 5. Gene regulation by p53 is cooperativity-dependent. (A) Correlation of the ChIP-seq data with the corresponding expression profiles
revealed 351 differentially expressed genes with 489 distinct binding sites. Expression levels of these genes are depicted in a heat map ranked by
decreasing EE/RR binding strength. The cooperativity classification of genes according to ChIP-seq is shown on the left as in Fig. 1D. Gene regulation
by p53 increases with DNA binding cooperativity and correlates with DNA binding strength as shown in the walking average plot of expression for
each p53 cooperativity mutant. (B) Expression of p53-bound and -regulated genes according to cooperativity. Shown is the log2-fold expression
change. The black horizontal bar indicates the mean. (C) DNA binding strength (in reads/peak) of wild-type p53 to low or high cooperativity sites in
differentially regulated genes. Depicted is a box-and-whiskers blot with 10/90 percentiles and the median; outliers are plotted as dots. *, p,0.001. (D)
Validation of microarray results by RTqPCR analysis. Shown is the mean (6SD, n = 3) log2-fold expression change. (E) Motif search (MEME), spacer
analysis (p53MH) and genomic classification of p53 binding sites in differentially regulated genes followed by functional annotation with GO terms as
in Fig. 2 and 3.
doi:10.1371/journal.pgen.1003726.g005
Figure 6. Role of DNA binding cooperativity for the survival of
breast cancer patients. (A,B) Kaplan-Meier survival estimates for
breast cancer patients [35,37] stratified on the basis of (A) high and (B)
low cooperativity target gene expression (Suppl. Table S4). Patients
with an upregulated expression (high_UP; low_UP) were plotted
against patients with a downregulation (high_DOWN; low_DOWN).
The number of patients at risk in each group at a given time point is
indicated below the plots. p-values from log-rank test and Monte-Carlo
simulations are indicated in the figure.
doi:10.1371/journal.pgen.1003726.g006
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Figure 7. p53-dependent gene repression requires high DNA binding cooperativity. (A) The percentage of differentially regulated genes
with or without a p53 binding site in our ChIP-seq dataset. (B) Genome browser views of distal p53 binding peaks that overlap with enhancer sites
marked by H3K4 mono- and dimethylation, H3K27 acetylation and DNase I hypersensitivity (HS) in four different cell lines (GM12878, HUVEC, NHEK,
HSMM; named in the order of appearance). The bars represent regions of statistically significant signal enrichment [UCSC browser tracks; 71]. (C)
Expression of p53-downregulated genes according to cooperativity. The black horizontal bar indicates the mean. (D) Validation of the microarray
results by RTqPCR analysis. (E) Expression analysis of indicated genes by RTqPCR analysis. (E–G) CDKN1A and E2F7 are transactivated in a
cooperativity-dependent manner (RTqPCR, E; immunoblot, F) and mediate p53-dependent repression of target genes (RTqPCR, G). nsi, non-silencing
control siRNA. All bar graphs in this figure show the mean (6SD, n = 3) log2-fold expression change. Two-tailed Mann-Whitney U test: *, p,0.05; **,
p,0.01. Bar colors are as indicated in (D).
doi:10.1371/journal.pgen.1003726.g007
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mutation when studied in vitro using recombinant proteins purified
from E. coli [22], the DNA binding defect of RR expressed in
mammalian cells was weaker and resulted in a cistrome of 1667
binding sites comprising mostly perfect consensus-like full-site
motifs in genes enriched for cell cycle regulators. Importantly,
while both EE and RR homotetramers have a more or less
reduced cooperativity, they complement each other efficiently to
yield EE/RR heterotetramers with a cooperativity higher than
wild-type p53. This increases the efficiency of cooperative DNA
binding and enables binding to a larger spectrum of 5188 sites
enriched for non-canonical, spacer-containing p53 motifs in, for
example, pro-apoptotic genes (Fig. 2 and 3). Together, these data
prove that DNA binding cooperativity is a crucial modulator of
p53’s genome-wide binding pattern (cistrome) with important
functional relevance for cell fate determination.
Previous ChIP-seq studies of activated wild-type p53 have
identified approximately 1800 to 2900 significant binding sites
[31,32], which is comparable to the number of 1667 peaks bound
by low cooperativity p53. Direct comparison of ChIP-seq data
from different cells treated with multiple p53-activating drugs
further revealed that the default set of p53 binding sites common
to most cell types and independent of the type of activating
stimulus largely comprises low cooperativity sites (Fig. 4). In
contrast, binding sites that were bound by p53 in a cell-type and
stress-specific manner were enriched in high cooperativity sites
(Fig. 4), suggesting that fine-tuning the p53 response in a context-
specific manner relies on DNA binding cooperativity.
On the DNA side, the interaction of p53 with a certain DNA
motif is largely influenced by the central CWWG sequence even
though the WW dinucleotide is not directly contacted by p53
[15,19,20]. As proper binding of the p53 tetramer to DNA
requires bending of the DNA, different affinities of CWWG
sequences can be explained by differences in bending flexibility
[14,20,45]. As CATG is the most flexible CWWG sequence,
intermolecular cooperation of p53 monomers is likely dispensable,
while efficient binding to the more rigid non-CATG may require
higher bending forces that depend on energetic stabilization
provided by strong H1 helix interactions [24,44]. Consistent with
high affinity binding of p53 to CATG, we identified a specific
enrichment of central CAWG sequences among the high affinity
sites that were bound irrespective of cooperativity (Fig. 2E). In
contrast, in line with lower affinity binding of p53 to CAAG,
CTTG or CTAG, these non-CATG sequences showed a stronger
dependence on cooperativity (Fig. 2E). Together, H1 helix
interactions allow p53 molecules to cooperate to provide sufficient
energy required for bending and binding a larger variety of
sequences in the genome.
Importantly, there is growing evidence that such non-canonical,
low affinity binding sites contribute substantially to p53’s function
[18]. First of all, considerable transactivation was observed at non-
canonical half-sites (single decamers) and three-quarter-sites, some
of which were originally classified as biologically relevant response
elements (REs) in, for example, the pro-apoptotic target genes
PIDD and APAF1 [17]. Moreover, REs in many other functionally
important pro-apoptotic genes show on average less similarity to
the p53 consensus sequence and a lower degree of evolutionary
conservation associated with higher sequence diversity than most
prototypic cell cycle target genes such as CDKN1A [13,16,46].
Another example is the VEGFR1 gene promoter, which contains a
single nucleotide polymorphism that generates a non-canonical,
functional p53 half-site thereby integrating the VEGF system into
the p53 transcriptional network [47]. In fact, it is discussed that
weak p53 REs have a selective advantage compared with high-
affinity p53 binding sites as they could allow better fine-tuning of
responses through the regulation of p53 protein levels, specific
post-translational modifications or cofactors that modulate DNA
binding affinity [18,44,48]. Crosstalk between p53 and the
estrogen receptor in regulating VEGFR1 provides a prominent
example for the functional dependence on cooperation of p53 with
other transcription factors for maximal activation of such non-
canonical response elements [49]. Cooperativity therefore dra-
matically expands the p53 transcriptional network allowing the
engagement of target genes that - likely as a safeguard - require a
higher degree of stress or damage for activation.
The integrated analysis of ChIP-seq with expression profiling
data revealed that less than 10% of the p53-bound genes were
regulated by p53 (Fig. 5). This is in line with other studies
[31,33,50,51], and indicates that p53 binding to DNA is often not
sufficient to induce transcription. Secondary stimuli or co-factors
are needed, possibly in a stress or cell type specific manner, to
induce a permissive chromatin state as previously suggested for
single p53 target gene promoters [52]. While binding sites of low
and high cooperativity p53 showed a similar distribution across the
genome and were in 70–80% located in the promoter region or
gene body (Fig. 2A,B), functional binding events that resulted in
expression changes were distributed differently. While binding
sites regulated by low cooperativity p53 were mainly enriched in
the promoter region of genes, binding sites regulated by high
cooperativity p53 were also frequently observed in the gene body
(Fig. 5E). As binding of p53 to the regulatory promoter is more
likely to have a direct effect on transcription than binding to a site
further downstream of the transcriptional start site, this finding is
consistent with the hypothesis that low affinity, non-canonical
binding sites primarily function in cooperation with other
transcription factors to fine-tune gene expression in response to
context- or tissue-specific stimuli [18].
Interestingly, our analysis on the role of DNA binding
cooperativity for patient survival showed a remarkable difference
between low and high cooperativity genes. While upregulated
expression of high cooperativity target genes correlated with a
good clinical outcome, expression of low cooperativity target genes
was surprisingly not correlated with distinct patient survival (Fig. 6).
This indicates that low and high cooperativity genes are clinically
not equivalent. Although low cooperativity genes comprise the
default program of target genes activated in most cell types in a
stimulus-independent manner, only the activation of high co-
operativity genes is able to prolong patient survival. Together these
data strongly emphasize the clinical relevance of DNA binding
cooperativity for the anti-cancer activity of p53.
Intriguingly, a number of studies from both breast cancer
patients and mice have found a wild-type p53 status to be
associated with an inferior clinical response to chemotherapy
compared to tumors with mutant p53 [53,54,55,56]. For example,
in MMTV-Wnt1 driven mouse mammary tumors p53 wild-type
tumor cells can evade an apoptotic chemotherapy response by
undergoing arrest, followed by secretion of senescence-associated
cytokines that can stimulate proliferation and relapse [53]. Given
the functional separation of the p53 cistrome into high
cooperativity genes with proapoptotic function and low coopera-
tivity genes involved in cell cycle arrest, it is tempting to speculate
that the expression ratio of high versus low cooperativity genes
might determine the clinical response to chemotherapy in p53
wild-type tumors. While activation of high cooperativity genes is
expected to prolong the long-term survival of the patient by
supporting the apoptotic chemotherapy response, activation of low
cooperativity genes leading to senescence might even be counter-
productive and promote relapse. In fact, there was a trend -
although not statistically significant - that in patients without
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upregulation of high cooperativity genes expression of low
cooperativity genes was associated with an inferior survival (data
not shown). Although it still remains to be investigated whether
cooperativity has a similar impact on patient survival in other
tumor entities, it is intriguing that the DNA binding cooperativity
of p53 is not only crucial for preventing tumor development [25]
but also appears to have a clinical impact on the survival of cancer
patients under therapy.
Overall 221 genes, significantly enriched for mitotic and
developmental regulators, were robustly repressed in response to
p53 activation (Fig. 7). This is consistent with numerous studies
that have established repression of cell cycle regulatory genes as a
function of p53 [5]. For example, p53 robustly downregulates the
MYC oncogene for induction of cell cycle arrest [57]. Surprisingly,
in contrast to half of all activated genes, only 13 of 221 repressed
genes showed p53 binding in the ChIP-seq experiment (Fig. 7A).
Although some studies have reported direct binding of p53 to non-
canonical p53 response elements in repressed genes, convincing
genome-wide data supporting direct p53 binding as a general
mechanism of repression is missing [5,6]. Of note, interference of
p53 with distal enhancer elements has been described to mediate
repression of stem cell specific genes in murine embryonic stem
cells [39]. We can confirm p53 binding to distal enhancers in two
cases (ADRB1, NUFIP1), but overall the mechanism does not seem
to play a prominent role in our cell model suggesting cell type
specificity (Fig. 7B).
Interestingly, despite the absence of p53 binding events at
repressed genes, the degree of repression was nevertheless
dependent on cooperativity (Fig. 7). Importantly, p53-mediated
repression of anti-apoptotic genes and oncogenes is crucial for
p53-induced apoptosis [12,58]. As cooperativity-reducing muta-
tions result in apoptosis deficiency [24] and impair both the
transactivation of important pro-apoptotic genes and the repres-
sion of a large set of genes, it is conceivable that cooperativity-
dependent repression contributes to the pro-apoptotic function of
p53. As p53 is not directly binding to most of the downregulated
genes (Fig. 7A), an indirect mechanism involving p53-mediated
transactivation of genes with repressor functions might be
underlying repression mechanistically. In support of this, mice
carrying a mutation in the p53 transactivation domain were
reported as strongly impaired not only for transactivation but also
repression [59]. Furthermore, a number of p53-activated genes
including CDKN1A and E2F7 have been implicated in repressing a
variety of p53-regulated genes [7,8,9]. Consistently, we identified
many E2F target genes as repressed by p53 and confirmed the
requirement of E2F7 and CDKN1A for the repression of mutually
exclusive sets of genes (Fig. 7F,G). As both, E2F7 and p21, are
induced in a cooperativity-dependent manner (Fig. 7F), their
regulation could contribute to the cooperativity-dependent
repression of at least a subset of p53-downregulated genes.
Furthermore, p53 has been implicated as a master regulator of
miRNAs expression and processing [43]. The by far best studied
group of p53-activated miRNAs is the miR-34 family that targets
many mitotic genes contributing to senescence and apoptosis
induction [10,60,61]. Other miRNAs induced by p53 such as
miR-145 or the miR-200 family have been implicated as inhibitors
of MYC and important developmental genes, respectively [43].
Our bioinformatics analysis of the cooperativity-dependently
repressed genes revealed several miRNAs as potential upstream
regulators, amongst others miR-34, miR-145 and miR-200. In
addition, p53 was shown to repress genes indirectly by upregulat-
ing the large intergenic non-coding RNA lincRNA-p21, which is
believed to interact with chromatin modifying complexes to silence
target genes [12]. We observe induction of lincRNA-p21 in our
study but do not see a major impact of cooperativity on lincRNA-
p21 expression, excluding this lincRNA as a cause of cooperativ-
ity-dependent gene repression.
In principle, cooperativity-dependent gene repression in the
absence of direct p53 binding to the repressed target promoters
could alternatively indicate that cooperativity mutations affect
other aspects of p53 function apart from DNA binding. While
cooperativity mutations - different from many hot-spot mutations -
do not affect the overall folding of the DNA binding domain [22],
it is known that amino acids E180 and R181 are engaged in p53
interactions with ASPP family proteins that stimulate p53-
transactivation of pro-apoptotic target genes [62,63]. Further-
more, it has been described that association of p53 with promoter-
specific cofactors like Sp1, SMAD3, NF-Y and YY1 results in gene
repression [5,6]. We applied both a sequence-based promoter
analysis and a search for common upstream regulators of the p53-
repressed genes and identified a significant enrichment of all these
factors. Whether the interaction of Sp1, SMAD3, NF-Y and YY1
with p53 is dependent on cooperativity has so far not been
explored. A future analysis of the interactome of p53 cooperativity
mutants might therefore reveal additional insight into the effect of
cooperativity mutations on gene repression.
In summary, our combined genome-wide analysis of DNA
binding and gene expression using a set of p53 mutants with
reduced and increased cooperativity reveals DNA binding
cooperativity as a major modulator of the p53 cistrome. In
particular the use of high cooperativity p53 enabled the
compilation of a comprehensive set of p53 binding sites including
many non-canonical response elements that have previously not
been profiled. Interestingly, cooperativity is revealed to be not only
important for p53 binding to non-perfect response elements but
also for p53-mediated gene repression. Since both transactivation
of non-canonical response element and p53-mediated repression
are crucial for p53’s pro-apoptotic activity, this strengthens the
concept that the requirement for intermolecular p53 cooperation
provides a novel safeguard mechanism protecting against the
accidental activation of apoptosis as the most final, irreversible cell
fate decision possible.
Materials and Methods
Cell culture, RNA interference and viral transduction
Saos-2 and U2OS cells were cultured in Dulbecco’s modified
Eagle’s medium (Life Technologies) supplemented with 10% fetal
bovine serum (PAA) and penicillin/streptomycin (Life Technolo-
gies) using standard conditions and procedures. siRNAs were
purchased from Dharmacon and transfected with Lipofectamine
RNAiMAX (Life Technologies) according to the manufacturer’s
protocol. Generation and use of recombinant adenoviruses for
wild-type p53 and p53R181E and p53E180R have been described
[24].
Chromatin immunoprecipitation (ChIP)
Saos-2 cells were infected with adenovirus encoding GFP (as a
control) or GFP together with wild-type or mutant p53. Cells were
fixed 18 hours after infection in fresh 1% paraformaldehyde (PFA)
for 10 min at room temperature (RT). Unreacted PFA was
quenched by adding glycine to a final concentration of 125 mM
for 5 min at RT. Cells were washed twice with ice-cold PBS and
scraped from the dishes in ice-cold phosphate buffered saline
supplemented with proteinase inhibitor (Complete, Roche). Cells
were pelleted (7006g for 5 min at 4uC) and lysed at a
concentration of 26107 cells/ml in SDS Lysis Buffer (1% SDS,
10 mM EDTA, 50 mM Tris pH 8.1) supplemented with protein-
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ase inhibitor. Cells were sonicated on ice in 1 ml aliquots 5
times at 30% power for 10 sec followed by a 50 sec pause with a
SONOPLUS sonifier with sonotrode MS72 (Bandelin electron-
ics, Germany). Agarose gel electrophoresis confirmed shearing
of crosslinked DNA into a smear in the range of 200–800 bp.
After centrifugation at 10,0006g for 10 min at RT supernatants
were diluted 1:10 with Dilution Buffer (0.01% SDS, 1.1%
Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1,
167 mM NaCl) and after 1 h of pre-clearing 1% input was
removed from each sample and proteins were precipitated with
p53 DO-1 antibody over night at 4uC. Mock-chromatin was
immunoprecipitated from cells infected with GFP only. Com-
plexes were bound to Protein G magnetic beads (Fast Flow, GE
healthcare) for 2 h at 4uC and washed once with Low Salt
Immune Complex Wash Buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), once
with High Salt Immune Complex Wash Buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1,
500 mM NaCl), once with LiCl Immune Complex Wash Buffer
(0.25 M LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid
(sodium salt), 1 mM EDTA, 10 mM Tris-HCl pH 8.1), and
twice with TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) for
about 5 min at 4uC. Complexes were eluted with Elution buffer
(1% SDS, 0.1 M NaHCO3) for 20 min at 800 rpm at RT.
Crosslinks were reversed at 65uC in 200 mM NaCl overnight
followed by RNase A (37uC, 30 min) and Proteinase K digestion
(45uC, 2 h). DNA was purified using the PCR Purification Kit
(Qiagen) and DNA concentration was measured with PicoGreen
(PicoGreen dsDNA Quantitation reagent, Molecular Probes).
The enrichment was verified by qPCR for known binding sites.
For primer sequences see Supplemental Table S3.
ChIP-seq
For each sample, a single library was sequenced once on an
Illumina GA IIx (ChIP-Seq Sample Preparation Kit, Cluster
Generation Kit v2, 36-Cycle Sequencing Kit v3) and twice on an
Illumina HiSeq2000 (TruSeq SR Cluster Kit v3 - cBot - HS,
TruSeq SBS Kit v3 - HS - 50 cycles) system.
Data analysis. In order to keep all mapping comparable,
only the first 36 bp of each read were used for further analysis.
Reads were aligned to the Homo sapiens genome retrieved from
Ensembl revision 65 with Bowtie 0.12.7 [64], using the parameter
setting: ‘-k 1 -n 2 -e 70 -m 1’ to retrieve only uniquely matching
reads with a low number of mismatches allowed. As a compromise
between filtering for PCR induced artifacts and the saturation of
the library complexity due to our read depth, read start positions
with more than 28 reads were limited to exactly 28 reads. The
resulting numbers of unique, perfectly matching reads were
34.3 M for the input, 37.6 M for the GFP control, 88.6 M for
wild-type p53, 31.2 M for EE, 84.1 M for RR and 100.4 M for
EE/RR.
Peak calling was performed separately on each sample using
only the GA IIx sequencing run, using PARTEK Genomics Suite
6.6 (St. Louis, MO, USA). The significance threshold for the
identification of enriched regions in the p53 samples was set to an
FDR of ,0.00001 and a P-value vs. GFP and input control of
P#0.05. An interval union of peaks from all samples was build and
peaks were annotated with the next gene as judged by distance to
the gene’s most 59 transcription start site. All gene annotations
were retrieved from Ensembl revision 65. To enable comparison
between the samples, combined tag counts from all sequencing
runs were formed, and normalized to 1 million mapped reads.
p53-presence was considered independently of the peak calling by
ranking the conditions at each peak by their normalized read
count and looking for at least a two fold difference between the
ranks. Depending on the first rank showing such a difference to the
previous, we designated the top one, two, three genotypes as
binding. If no such ‘gap’ was found, we considered all genotypes as
present. Binding profiles of p53 at selected genomic regions were
visualized using PARTEK Genomics Suite 6.6 (St. Louis, MO,
USA).
Motif discovery. Peaks were analyzed for enriched sequence
motifs with MEME-ChIP [65]. Briefly, MEME-ChIP randomly
selects 600 input sequences, which are then trimmed (central
100 bp) before entering the MEME algorithm. The discovered
motifs were compared with known motifs from the JASPAR
database using TOMTOM [66]. In addition, all identified peak
sequences were analyzed with the spacer-tolerant p53MH
algorithm for spacer length and the top scoring p53 full-site
[27]. Further motif search and quality assessment was performed
with the FIMO [67] and MAST [68] algorithm. More cis-
regulatory factors were identified by Ingenuity Pathway Analysis
(Ingenuity Systems) and GeneXplain [42].
Functional annotation. Pathway and biological process
analyses were performed with Ingenuity Pathway Analysis
(Ingenuity Systems) and the gene sets of the Molecular Signatures
Database (MSigDB) v3.0 [69] and GATHER [70].
Comparison with ChIP-seq data from the
literature. Previously published p53 ChIP-seq data were
retrieved from the NCBI Gene Expression Omnibus
(GSM545807, GSM 545808 and GSM545809, [31]) and supple-
mental data [32]. Peak data were extracted and lifted over to
human genome assembly 19 (hg19). As reference genome we used
the human genome assembly GRCh37 for all analyses (http://
www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/
index.shtml). Peak lists were subsequently intersected to obtain
the number of common peaks in two or more ChIP-seq
analyses. Peaks were considered common if they overlap by at
least one bp.
Gene Set Enrichment Analysis, Kaplan-Meier estimates
and Monte Carlo simulations. To assess whether high or low
cooperativity target genes are relevant for patient survival, a
bioinformatics strategy based on Gene Set Enrichment Analysis
[38,69] was used to analyze gene expression datasets from two
separate breast cancer studies [35,37]. In detail, each gene
expression dataset was mean-centered across samples in log
scale and genes were ranked according to their expression level
relative to the dataset mean as described [38]. To define high
and low cooperativity gene sets the p53-bound and -regulated
genes from Supplemental Table S1 were grouped into two sets
based on the cooperativity classification of their p53 binding
peak (Supplemental Table S4). Genes that had both low and
high cooperativity peaks were considered as low cooperativity
genes. Subsequently, for both the high and low cooperativity
gene set enrichment scores were calculated for each tumor
patient expression profile as described [38,69]. The obtained
enrichment scores were used to calculate Kaplan-Meier survival
estimates for each gene set by separating patients into two
groups, based on whether the obtained enrichment score was
positive or negative. Statistical significance was assessed using
the log-rank test. Furthermore, we performed Monte-Carlo
simulations with 10,000 randomly generated gene signatures of
equal size and used the obtained Kaplan-Meier estimates to
calculate p-values.
RNA isolation, RTqPCR and expression profiling
RNA isolation and cDNA synthesis were performed using the
RNeasy Mini Kit (Qiagen) and SuperScript VILO cDNA
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Synthesis Kit (Life Technologies). miRNA isolation was performed
using the mirVana miRNA Isolation Kit (Life Technologies)
followed by reverse transcription using the TaqMan miRNA
Reverse Transcription Kit (Life Technologies). Gene expression
was quantified by RTqPCR using SYBR Green Jumpstart Taq
ReadyMix (Sigma) or TaqMan MicroRNA Assays (U6 snRNA,
miR-34a; Life Technologies) on a LightCycler 480 (Roche).
Expression data were normalized to GAPDH or U6 snRNA and the
mock sample using the DDCt method. For primer sequences see
Supplemental Table S3.
cDNA microarrays. cRNA of the Saos-2 cells expressing
different p53 versions was prepared and hybridized to an
oligonucleotide microarray (Human Genome U133 Plus 2.0
Array, Affymetrix) according to the manufacturers’ instructions.
The obtained expression signals were processed with the
GeneChip Expression Console Software (Affymetrix) using the
MAS 5.0 Data Processing Protocol. The expression fold change of
each p53 version vs. GFP control cells was calculated and log2-
transformed.
SDS-PAGE, immunoblotting
Cells were lysed in 50 mM Tris-HCl pH 8.0, 150 mM NaCl,
5 mM EDTA pH 8.0, 2% Nonidet P-40 and the total protein
concentration was quantified by Bradford assay. Samples were
separated by SDS–PAGE and transferred onto nitrocellulose
membranes (GE healthcare). After blocking with 10% non-fat dry
milk, membranes were probed with antibodies specific for p53
DO-1 (gift from B. Vojtesek), CDKN1A (C-19, Santa Cruz), E2F7
(H-300, Santa Cruz), or b-actin (AC15, Abcam). Enhanced
chemiluminescence (Thermo Scientific) or fluorescence (Odyssey
Infrared Imaging System, LI-COR) was used for detection.
Data access
ChIP-seq data have been deposited in the EBI ArrayExpress
archive (http://www.ebi.ac.uk/arrayexpress/) and are accessible
through the accession numbers E-MTAB-1394 (Username:
Reviewer_E-MTAB-1394; Password: 0vmiovxP)
Microarray data sets have been deposited in the EBI
ArrayExpress archive (http://www.ebi.ac.uk/arrayexpress/) and
are accessible through the accession number E-MTAB-1403
(Username: Reviewer_E-MTAB-1403; Password: srkaaska)
Supporting Information
Table S1 List of 489 p53-bound genes showing a p53-dependent
expression change by more than 2-fold for at least one of the p53
variants. Shown are the location of the p53 binding peak, the
distance to the next neighboring gene, normalized read count per
peak, classification of peak localization according to gene
structure, classification according to cooperativity group and
log2-fold expression change versus GFP-control.
(XLSX)
Table S2 List of 221 genes showing a p53-dependent downreg-
ulation by more than 2-fold for at least one of the p53 variants.
Shown are the log2-fold expression change versus GFP-control
and the presence or absence of a p53 binding peak in the genomic
neighborhood.
(XLSX)
Table S3 Primer sequences for RTqPCR and ChIP-qPCR.
(XLSX)
Table S4 List of p53-bound genes showing a p53-dependent
expression change by more than 2-fold versus GFP-control for at
least one of the p53 variants. Genes are divided into low and high
cooperativity genes based on ChIP-seq results (Table S1). Genes
with a low cooperativity peak were denoted as low cooperativity
target genes, genes with a high cooperativity peak as high
cooperativity target genes. Genes with both low and high
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